Tempus AI has acquired Paige, a leader in digital pathology and developer of FDA-cleared AI tools for cancer detection, in a deal valued at $81.25 million. The agreement includes covering Paige’s remaining commitments to Microsoft Azure and will be paid largely in Tempus stock.
Paige brings to Tempus a vast dataset of nearly 7 million digitized pathology slides and clinical data from its partnership with Memorial Sloan Kettering Cancer Center. In addition, Paige has developed a foundation AI model trained on more than 2.3 million whole-slide images spanning hundreds of thousands of patient cases.
Earlier this year, Tempus launched a $200 million collaboration with AstraZeneca and Pathos AI to build a multimodal cancer model. According to Tempus founder and CEO Eric Lefkofsky, Paige’s expertise and dataset will accelerate these efforts:
“As we embark on building the largest foundation model in oncology, the acquisition of Paige substantially accelerates our mission. Paige’s deep generative AI experience and unparalleled dataset will be catalytic across our AI initiatives.”
Paige recently unveiled PRISM2, an AI program co-developed with Microsoft Research, designed to link tissue sample image patterns with clinical descriptions. This innovation aims to enhance drug development, diagnostic biomarkers, and patient outcome prediction.
Paige’s CEO and CTO Razik Yousfi said the partnership will expand access to its innovations:
“The future of cancer care lies in AI-powered digital pathology. By joining Tempus, we can bring these breakthroughs to more patients worldwide.”